Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05543798

VT Ablation in the iCMR

Led by Imricor Medical Systems · Updated on 2026-01-08

64

Participants Needed

3

Research Sites

111 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The VISABL-VT is a prospective, single-arm, multi-center, interventional investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.

CONDITIONS

Official Title

VT Ablation in the iCMR

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Roll-in subjects only: Documentation of premature ventricular contractions indicated for ablation therapy (subjects may or may not be diagnosed with Ischemic Cardiomyopathy)
  • Documented (ECG/EGM) spontaneous episode of sustained ventricular tachycardia within 6 months of the procedure
  • Diagnosis of Ischemic Cardiomyopathy
  • AAD therapy refractory, contraindicated, not tolerated, or not desired
  • 18 years or older
Not Eligible

You will not qualify if you...

  • Implanted with non-MR compatible medical devices or contraindicated for an MRI
  • Presence of intracardiac thrombus (verified via CT/MRI/TEE/TTE within 48 hours of procedure or at start of procedure)
  • Thrombocytopenia or coagulopathy
  • Mechanical mitral and/or aortic valve precluding access to the left ventricle
  • Severe aortic stenosis
  • Myocardial infarction requiring stent implantation within 90 days of procedure
  • Previous cardiac surgery within 60 days of procedures
  • Known or uncontrolled stroke risks
  • Class IV Heart Failure
  • Ejection Fraction (EF) less than 25%
  • Patients with a glomerular filtration rate (GFR) less than 30
  • Women who are pregnant
  • Allergy to contrast agents (e.g., Gadolinium)
  • Active infection
  • Known or suspected myxoma
  • Unstable angina
  • Patients who do not tolerate anticoagulation therapy
  • Previous intertribal septal patch or prosthetic atrial septal defect closure device
  • Life expectancy less than 12 months
  • Enrollment in another study without sponsor approval

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Herzzentrum Leipzig

Leipzig, Saxony, Germany, 04289

Not Yet Recruiting

2

Amsterdam UMC

Amsterdam, Netherlands

Actively Recruiting

3

HagaZiekenhuis

The Hague, Netherlands, 2545 AA

Not Yet Recruiting

Loading map...

Research Team

K

Kate Lindborg, Phd

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

VT Ablation in the iCMR | DecenTrialz